CancerTYPE ID^® publications and
scientific presentations

Publications

Molecular Classification of Human Cancers Using a 92-Gene Real-Time Quantitative Polymerase Chain Reaction Assay
Ma, XJ et. al. Archives of Pathology & Laboratory Medicine. April 2006, Volume 130, Number 4. 465–473.

Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction
Greco, FA et al. The Oncologist. 2010;15:500-506.

Molecular Classification of Cancers of Unknown Primary Site
Greco, FA; Erlander, MG. Mol Diagn Ther. 2009 Dec 1;13(6):367-73.

Evolving Understanding and Current Management of Patients with Cancer of Unknown Primary Site
Greco, FA. Commun Oncol. 2010;7:183-188.

Molecular Classification of Unknown Primary Cancer
Bender, RA; Erlander, MG. Sem Oncol. 2009;36:38-43.

Gene-Expression Profiling and Cancer of an Unknown Primary Origin
Acevedo, P; Castro, V. Commun Oncol. 2008;5:590-592.

Scientific presentations

Treatment of Carcinoma of Unknown Primary Site (CUP) Directed by Molecular Profiling Diagnosis: A Prospective, Phase II Trial
Hainsworth, JD et al. American Society of Clinical Oncology Annual Meeting Poster Presentation, June, 2010.

Unknown Primary Cancer (UPC): Accuracy of Tissue of Origin Prediction by Molecular Profiling
Greco, FA et al. American Society of Clinical Oncology Annual Meeting Poster Presentation, May/June, 2009.

Psychosocial Aspects of Treating Patients with Cancer of Unknown Primary (CUP): A Survey of Oncology Social Workers
McCormick, BK; Erlander, MG.Association of Oncology Social Work Annual Conference Poster Presentation, May, 2009.

Molecular Classification of Cancer: Implications for Carcinoma of Unknown Primary
Erlander, MG. United States and Canadian Academy of Pathology meeting, AMP companion meeting, March 25, 2007.

Molecular Classification of Tumor of Unknown Origin by Gene-Expression from Fixed Paraffin Embedded Tissue
Erlander, MG et al. American Society of Clinical Oncology, June 2004.

Breast Cancer Index^SM publications and scientific presentations

Publications

A Five-Gene  Molecular Grade Index and HOXB13:IL17BR are Complementary Prognostic Factors in Early Stage Breast Cancer
Ma XJ, et al. Clin Cancer Res. 2008 14(9):2601-8.

Exploring the Two-Gene Ratio in Breast Cancer – Independent Roles for HOXB13 and IL17BR in Prediction of Clinical Outcome
Jerevall JL, et al. Breast Cancer Research Treatment. 2008 107(2):225-34.

The Prognostic Biomarkers HOXB13, IL17BR, and CHDH are Regulated by Estrogen in Breast Cancer
Wang Z et al. Clinical Cancer Research. 2007 13(21):6327-6334.

The HOXB13:IL17BR Expression Index is a Prognostic Factor in Early-Stage Breast Cancer
Ma XJ, et al. Journal of Clinical Oncology. October 2006 24(28):4611-4619.

A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen
Goetz MP, et al. Clinical Cancer Research. April 2006 12: 2080-2087.

A Two-Gene Expression Ratio Predicts Clinical Outcome in Breast Cancer Patients Treated with Tamoxifen
Ma XJ, et al. Cancer Cell 2004 5:607-616.

Gene Expression Profiles of Human Breast Cancer Progression
Ma XJ, et al. Proc Natl Acad Sci 2003 100(10):5974-9.

Scientific presentations

Predictive Value of the The Breast Cancer Index (TBCI) for Distant Recurrence and Overall Survival (OS) in Comparison to Adjuvant! Online and Clinicopathologic Characteristics in Women with Lymph Node (LN)-negative, ER-positive Breast Cancer (BCa)
American Society of Clinical Oncology Poster, June  2010.

Prognostic Utility of HOXB13:IL17BR and Molecular Grade Index for Node-negative Breast Cancer Patients
San Antonio Breast Cancer Symposium Poster Presentation, December 2009.

HOXB13 May Predict Response to Neoadjuvant Letrozole in Patients with Estrogen Receptor-positive Breast Cancer
San Antonio Breast Cancer Symposium Poster Presentation, December 2009.

Validation of Prognostic Utility of HOXB13:IL17BR and Molecular Grade Index in Early Stage Breast Cancer
San Antonio Breast Cancer Symposium Abstract, December 2009.

A Robust Five-Gene RT-PCR Molecular Grade Index Stratifies Recurrence Risk for Grade 2 Tumors, Predicts Chemo-Sensitivity and is Compatible with Formalin-Fixed Paraffin-Embedded Tissue
Miami Breast Cancer Conference Poster, February 2008.

Molecular Grade Index (MGI) and H:I Ratio are Complementary Prognostic Factors in Breast Cancer
American Society of Clinical Oncology Poster, September 2007.

HOXB13 to IL17BR Gene Expression Ratio is not Associated with Tumor Infiltrating Lymphocytes in Estrogen Positive, Node Negative Breast Cancer
American Association for Cancer Research, 2007.

The HOXB13:IL17BR Expression Index is a Prognostic Factor in Early-Stage Breast Cancer
San Antonio Breast Cancer Symposium, December 2005

A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen
San Antonio Breast Cancer Symposium, December 2005